| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $33,624,000 | 2 | 67 |
Sells | $1,021,211 | 1 | 33 |
| RA CAPITAL MANAGEMENT, L.P. | 1 | $32.99M | 0 | $0 | $32.99M | |
| Flynn James E | Possible Members of 10% Group | 1 | $630,000 | 0 | $0 | $630,000 |
| Meisner Lara | Chief Legal Officer | 0 | $0 | 1 | $1.02M | $-1.02M |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Over the last 12 months, insiders at Bicara Therapeutics Inc. Common Stock have bought $33.62M and sold $1.02M worth of Bicara Therapeutics Inc. Common Stock stock.
On average, over the past 5 years, insiders at Bicara Therapeutics Inc. Common Stock have bought $33.62M and sold $1.02M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $32.99M. Flynn James E (Possible Members of 10% Group) — $630,000.
The last purchase of 35,000 shares for transaction amount of $630,000 was made by Flynn James E (Possible Members of 10% Group) on 2024‑09‑17.
| 2025-03-14 | Sale | Meisner Lara | Chief Legal Officer | 79,146 0.1511% | $12.90 | $1.02M | +6.76% | |
| 2024-09-17 | Flynn James E | Possible Members of 10% Group | 35,000 0.045% | $18.00 | $630,000 | -43.61% | ||
| 2024-09-16 | RA CAPITAL MANAGEMENT, L.P. | 1.83M 2.6517% | $18.00 | $32.99M | -39.74% |
| Increased Positions | 56 | +64.37% | 8M | +16.45% |
| Decreased Positions | 34 | -39.08% | 5M | -11.8% |
| New Positions | 30 | New | 1M | New |
| Sold Out Positions | 17 | Sold Out | 3M | Sold Out |
| Total Postitions | 109 | +25.29% | 49M | +4.66% |
| Ra Capital Management, L.P. | $100,862.00 | 12.65% | 6.96M | 0 | 0% | 2024-12-31 |
| Siren, L.L.C. | $47,456.00 | 5.95% | 3.27M | +200,000 | +6.51% | 2024-12-31 |
| Red Tree Management, Llc | $45,972.00 | 5.77% | 3.17M | +3M | New | 2024-12-31 |
| Tpg Gp A, Llc | $43,651.00 | 5.47% | 3.01M | 0 | 0% | 2024-12-31 |
| Omega Fund Management, Llc | $31,967.00 | 4.01% | 2.2M | 0 | 0% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $31,541.00 | 3.96% | 2.18M | +1M | +171.91% | 2024-12-31 |
| Fmr Llc | $30,698.00 | 3.85% | 2.12M | -156,704 | -6.89% | 2024-12-31 |
| Braidwell Lp | $29,010.00 | 3.64% | 2M | +343,059 | +20.7% | 2024-12-31 |
| Deep Track Capital, Lp | $29,000.00 | 3.64% | 2M | +1M | +150.99% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $26,030.00 | 3.26% | 1.8M | 0 | 0% | 2024-12-31 |